Psychedelic Business News Spotlight: May 7, 2021
This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.
Entries by
NIMH Supports 8 Interventions for Severe Suicide Risk Including Ketamine, Esketamine
New treatment interventions approved by NIMH for use with high-suicide risks include two novel ketamine therapies.
Ketamine Effectively Treats Persistent Migraine Headaches: Study
A nasal spray of ketamine proved to be highly effective at treating a type of migraine called refractory migraines, according to a new study.
MindMed’s Project Angie to Explore LSD for Chronic Pain Treatment
Psychedelic life sciences company MindMed is exploring LSD as a means of pain management.
Canada Approves New Leaf’s Bid to Build First-Of-Its-Kind Psilocybin Lab
New Leaf Canada has received permission from Health Canada to build a first-of-its-kind laboratory to produce and study psilocybin and psilocin.
Psychedelic Companies Combine Forces to Create Virtual Reality Experience
A new psychedelic VR experience is coming thanks to a partnership between Lobe Sciences and Virtual Psychedelics.
Promising Results from First Phase-3 Trial Investigating MDMA-Assisted Therapy for PTSD
The first phase-3 trial of its kind investigating MDMA for PTSD is showing promising results.
Researchers Discover Therapeutic Potential of Non-Hallucinogenic Psychedelic
Researchers have identified a psychedelic with no hallucinogenic characteristics using a new sensor.
Former NFL Player Kerry Rhodes Discusses Ayahuasca Experience With Tamron Hall
Actor and former NFL safety Kerry Rhodes says the psychedelic compound ayahuasca has helped him recover from brain injuries.
Maine Bill Seeks to Legalize Therapeutic Use of Psilocybin
Maine could soon become the second U.S. state to legalize the use of medicinal psilocybin for therapeutic use.
